Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA.
Ann Pharmacother. 2023 Sep;57(9):1062-1075. doi: 10.1177/10600280221144055. Epub 2023 Jan 12.
To assess the role of psychedelics in the treatment of anxiety or depression among patients with cancer.
PubMed search from inception to March 11, 2022, using the terms anxiety, depression, psychedelics, psilocybin, lysergic acid, methylenedioxymethamphetamine, or ayahuasca.
Studies assessing patients with cancer receiving psychedelics for the treatment of anxiety or depression.
Five unique randomized, double-blind, placebo-controlled trials were conducted. Significant reductions were found in 2 trials with 2 anxiety scales (State-Trait Anxiety Inventory-State, State-Trait Anxiety Inventory-Trait) and in 1 trial with 2 additional anxiety scales (Hamilton Rating Scale-Anxiety, Hospital Anxiety and Depression Scale-Anxiety). Significant reductions were found in 2 trials in 2 depression scales (Hospital Anxiety and Depression Scale-Depression, Beck Depression Inventory) and in 1 trial with an additional depression scale (Hamilton Rating Scale-Depression). Two studies assessed for clinically relevant reductions in anxiety and depression scores, and they occurred much more commonly in psychedelic-treated patients than those given placebo.
There is a new potential option for treating patients with anxiety and depression along with cancer, which is important given the generally lackluster benefits with traditional antidepressants. Only a few sessions may also provide benefits extending out for 6 to 12 months and possibly beyond that. However, the studies were small, had many methodological limitations, and there were increases in blood pressure and heart rate.
Psychedelics have a unique mechanism of action that might be well suited for treating anxiety and depression associated with cancer. This offers new promise for patients who are not being sufficiently treated with current antianxiety or antidepressant medications.
评估迷幻剂在治疗癌症患者焦虑或抑郁中的作用。
从建起到 2022 年 3 月 11 日,在 PubMed 上使用焦虑、抑郁、迷幻剂、裸盖菇素、麦角酸、亚甲二氧基甲基苯丙胺或卡瓦胡椒等术语进行搜索。
评估接受迷幻剂治疗焦虑或抑郁的癌症患者的研究。
进行了五项独特的随机、双盲、安慰剂对照试验。在 2 项使用 2 种焦虑量表(状态-特质焦虑量表-状态、状态-特质焦虑量表-特质)的试验和 1 项使用 2 种附加焦虑量表(汉密尔顿焦虑量表、医院焦虑和抑郁量表-焦虑)的试验中发现了显著减少。在 2 项使用 2 种抑郁量表(医院焦虑和抑郁量表-抑郁、贝克抑郁量表)的试验和 1 项使用附加抑郁量表(汉密尔顿抑郁量表)的试验中发现了显著减少。两项研究评估了焦虑和抑郁评分的临床相关减少,并且在接受迷幻剂治疗的患者中比接受安慰剂的患者更常见。
对于患有癌症的焦虑和抑郁患者来说,这是一种新的潜在治疗选择,鉴于传统抗抑郁药的益处通常乏善可陈,这一点非常重要。仅几次治疗也可能带来长达 6 至 12 个月甚至更长时间的益处。然而,这些研究规模较小,存在许多方法学限制,并且血压和心率升高。
迷幻剂具有独特的作用机制,可能非常适合治疗与癌症相关的焦虑和抑郁。这为那些当前抗焦虑或抗抑郁药物治疗效果不佳的患者带来了新的希望。